Accurate control of gene expression is essential for normal development and dysregulation
of transcription underpins cancer onset and progression. Similar to cell cycle regulation …

Drugs targeting the cell cycle–regulatory cyclin-dependent kinase (CDK) 4 and 6 have been
approved for the treatment of hormone receptor–positive breast cancer, and inhibitors …

Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …

PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced
neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically …

Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …

Purpose: DNA damage repair (DDR) defects are common across cancer types and can
indicate therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer …

Background CDK12 genomic alterations occur in several tumor types, but little is known
about their oncogenic role and clinical significance. Objective To describe the landscape of …

Abstract Purpose: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as
a biomarker of response to immunotherapy for metastatic castration-resistant prostate …

Abstract Cyclin-dependent kinase 12 (CDK12) is a member of the CDK family of proteins
(CDK) and is critical for cancer development. Years of study into CDK12 have generated …

Steroid hormone signaling induces vast gene expression programs which necessitate the
local formation of transcription factories at regulatory regions and large-scale alterations of …